OBJECTIVES: Individuals with Type 1 diabetes (T1DM) have been reported to require five times more secondary care support than non-diabetic individuals1. Basal insulin analogue (BIA) is increasingly used in people with T1DM to facilitate insulin dose titration while reducing the increased risks of nocturnal hypoglycemia. This study describes the prevalence of metabolic and micro-vascular complications of TIDM among a basal insulin analogue-switch cohort.

METHODS: Population-based retrospective cohort study using CPRD-HES linked data. Adult English patients with TIDM who switched from a first to a first/second generation BIA were analyzed. Index was defined as when a patient switched BIA. Healthcare and outcomes pre-and-post index were analyzed and described.

RESULTS: 15,233 individuals (female 49.9%) were included, with a mean (SD) age at index of 40.5 (15.9) years. Mean (SD) duration from diabetes diagnosis to index date was 18.7 (13.7) years, and weight, 75.81kg (16.89), (n=14,983). The mean (SD) baseline HbA1c was 8.94% (1.85), n=11,167. Index of Multiple Deprivation quintiles were relatively even.

CONCLUSIONS: With over three-quarters of the cohort previously hospitalized for T1DM-related complication and over 80% affected with at least one microvascular complication, T1DM still exerts a high burden on patients and the health system, even in the medium-term, including among those on BIAs. Within the contemporary therapeutic management of T1DM, there is a space for technologies that can fundamentally alter the course of T1DM to reduce the cumulative lifetime burden of the disease.